-
公开(公告)号：US20240148823A1
公开(公告)日：2024-05-09
申请号：US18461912
申请日：2023-09-06
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
IPC: A61K38/13 , A61K9/00 , A61K31/277 , A61K31/4164 , A61K31/43 , A61K31/4545 , A61K31/47 , A61K31/4725 , A61K31/473 , A61K31/496 , A61K31/545 , A61K31/55 , A61K31/56 , A61K31/573 , A61K31/58 , A61K31/65 , A61K31/7048 , A61K45/06 , A61L27/20 , A61L27/54
CPC classification number: A61K38/13 , A61K9/0043 , A61K31/277 , A61K31/4164 , A61K31/43 , A61K31/4545 , A61K31/47 , A61K31/4725 , A61K31/473 , A61K31/496 , A61K31/545 , A61K31/55 , A61K31/56 , A61K31/573 , A61K31/58 , A61K31/65 , A61K31/7048 , A61K45/06 , A61L27/20 , A61L27/54
Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.
-
公开(公告)号：US09517200B2
公开(公告)日：2016-12-13
申请号：US15069647
申请日：2016-03-14
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
IPC: A61F13/00 , A61F2/00 , A61K9/14 , A61K38/00 , A61N1/30 , A61M31/00 , A61M37/00 , A61F2/02 , A61F2/28 , A61K9/00 , A61K31/137 , A61K31/485 , A61K31/473 , A61K38/18 , A61K47/36 , A61K47/38
CPC classification number: A61K9/0085 , A61K31/137 , A61K31/473 , A61K31/485 , A61K38/18 , A61K38/185 , A61K47/36 , A61K47/38 , A61M31/00
Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.
-
公开(公告)号：US20230111968A1
公开(公告)日：2023-04-13
申请号：US17851613
申请日：2022-06-28
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier , Angela Nocera
IPC: G01N33/68 , A61K9/00 , A61K45/06 , A61K31/277 , A61K31/4725 , A61K31/496 , A61K31/4164 , A61K31/4545 , A61K31/473 , A61K31/55 , A61K38/13
Abstract: Methods for identifying and optionally treating subjects, e.g., subjects who have Chronic Rhinosinusitis (CRS), based on the detection of elevated levels of soluble P-glycoprotein in nasal secretions. The methods of treatment can include administration of a therapeutically effective amount of a P-glycoprotein inhibitor.
-
公开(公告)号：US11007246B2
公开(公告)日：2021-05-18
申请号：US16725213
申请日：2019-12-23
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
IPC: A61K31/277 , A61K38/13 , A61L27/20 , A61L27/54 , A61K9/00 , A61K45/06 , A61K31/4164 , A61K31/43 , A61K31/4545 , A61K31/47 , A61K31/4725 , A61K31/473 , A61K31/496 , A61K31/545 , A61K31/55 , A61K31/56 , A61K31/573 , A61K31/58 , A61K31/65 , A61K31/7048
Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.
-
公开(公告)号：US12295933B2
公开(公告)日：2025-05-13
申请号：US17442730
申请日：2020-03-24
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
IPC: A61K31/277 , A61K9/00 , A61K45/06 , A61P11/02
Abstract: Methods and compositions for the treatment of rhinosinusitis in a subject using topical verapamil.
-
Patent Agency Ranking
公开(公告)号：US20210023295A1
公开(公告)日：2021-01-28
申请号：US16968093
申请日：2019-02-08
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
Abstract: The present disclosure relates to apparatuses and methods of depot delivery of therapeutic agents. The apparatuses provide a drug delivery device including a catheter component having a stem portion and a branch portion. The catheter component includes a pre-defined bend such that the branch portion is angled with respect to the stem portion at an obtuse angle. The branch portion includes a dissecting head and at least one delivery port. The device includes a dilation balloon positioned on the branch portion between the pre-defined bend and the dissecting head, a drug delivery reservoir fluidly coupled to the at least one drug delivery port and a handle portion.
-
公开(公告)号：US20170348384A1
公开(公告)日：2017-12-07
申请号：US15687074
申请日：2017-08-25
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
IPC: A61K38/13 , A61K9/00 , A61K45/06 , A61K31/7048 , A61K31/65 , A61K31/58 , A61K31/573 , A61K31/56 , A61K31/55 , A61K31/545 , A61K31/496 , A61K31/473 , A61K31/4725 , A61K31/47 , A61K31/4545 , A61K31/43 , A61K31/4164 , A61K31/277 , A61L27/20 , A61L27/54
CPC classification number: A61K38/13 , A61K9/0043 , A61K31/277 , A61K31/4164 , A61K31/43 , A61K31/4545 , A61K31/47 , A61K31/4725 , A61K31/473 , A61K31/496 , A61K31/545 , A61K31/55 , A61K31/56 , A61K31/573 , A61K31/58 , A61K31/65 , A61K31/7048 , A61K45/06 , A61L27/20 , A61L27/54 , A61K2300/00 , C08L1/28 , C08L5/04 , C08L5/08
Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.
-
公开(公告)号：US20160193145A1
公开(公告)日：2016-07-07
申请号：US15069647
申请日：2016-03-14
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
IPC: A61K9/00 , A61K38/18 , A61K47/36 , A61K31/137 , A61K47/38
CPC classification number: A61K9/0085 , A61K31/137 , A61K31/473 , A61K31/485 , A61K38/18 , A61K38/185 , A61K47/36 , A61K47/38 , A61M31/00
Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.
Abstract translation: 提供了将至少一种药剂递送到受治疗者的中枢神经系统（CNS）的方法，治疗受试者的神经障碍或疼痛的方法，包括将至少一种药剂施用于颅骨的颅底中的SEM移植物 主题。 还提供了治疗受试者的神经障碍或疼痛的方法，包括在受试者的颅底中形成SEM移植物，并将至少一种药剂施用于受试者的颅底中的SEM移植物上。 还提供了在受试者的颅底中形成SEM移植物的方法，用于施用到颅底中的SEM移植物或受试者中的鼻内储存器或鼻内贮存器装置中的组合物，以及用于将这些组合物施用于SEM的装置 移植在受试者的颅底。
-
9.发明授权公开(公告)号：US12121608B2
公开(公告)日：2024-10-22
申请号：US17338505
申请日：2021-06-03
Inventor： Mansoor M. Amiji , Smrithi Padmakumar , Benjamin S. Bleier
CPC classification number: A61K9/0004 , A61K9/0043 , A61K47/34
Abstract: A method of delivering a therapeutic agent into the central nervous system through the blood-brain barrier includes implanting an implant within the submucosal space of the olfactory epithelium. The implant can provide sustained drug delivery to the brain. The implant can be placed using a minimally invasive surgical approach.
-
公开(公告)号：US20240181231A1
公开(公告)日：2024-06-06
申请号：US18284637
申请日：2022-03-28
Applicant: Massachusetts Eye and Ear Infirmary
Inventor： Benjamin S. Bleier
IPC: A61M31/00
CPC classification number: A61M31/002 , A61M2205/04 , A61M2205/10 , A61M2210/0618
Abstract: The present disclosure relates to systems, apparatuses, and methods of continuous delivery of therapeutic agents. The apparatuses provide an implantable device that can be implanted in a nasal region of a subject to enable continuous administration of a therapeutic agent to the central nervous system (CNS) of the subject. The implantable device for drug delivery can include a distal body having a wall extending from a proximal end to a distal end, and a lumen extending therethrough in a longitudinal direction. The distal body can include one or more apertures in fluid communication with the lumen and located along the wall, and a pair of support members protruding from the body in a transverse direction and extending along the body in the longitudinal direction. The support members can be separated by a gap distance that extends along in the longitudinal direction.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.02 seconds)
